Ultralife Corporation Reports Fourth Quarter Results

February 4, 2021 7:00 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

NEWARK, N.Y., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported GAAP EPS of $0.13, Adjusted EPS of $0.17 and operating income of $1.2 million on revenue of $29.0 million for the fourth quarter ended December 31, 2020 compared to GAAP EPS of $0.10, Adjusted EPS of $0.13 and operating income of $2.5 million on revenue of $31.0 million for the fourth quarter of 2019.

For fiscal 2020, Ultralife produced GAAP EPS of $0.33, Adjusted EPS of $0.41 and operating income of $5.7 million on revenue of $107.7 million compared to GAAP EPS of $0.32, Adjusted EPS of $0.40 and operating income of $7.4 million on revenue of $106.8 million for 2019. In addition, during 2020, the Company reduced the debt related to its May 2019 acquisition of Southwest Electronic Energy Corporation by $15.8 million, or 91.5%, to $1.5 million as of December 31, 2020 while increasing its year-end cash-on-hand by $3.2 million, or 43.9%, to $10.7 million.

“Fourth quarter operating results were in line with our internal expectations and reflect the continuing negative economic impact of the global pandemic, including oil & gas market sluggishness. Battery & Energy Products medical sales were up 94% and government/defense sales were up 19%, yet these were offset by reductions in oil & gas and Communications Systems sales. During the quarter, we also recognized a $1.6 million gain upon resolution of Ultralife’s claim in a class action lawsuit,” said Michael D. Popielec, President and Chief Executive Officer.

“Notwithstanding the unprecedented challenges we faced during 2020, results for the year demonstrate the resiliency of our business model, the efficacy of our end-market diversification strategy and the strength of our balance sheet. We grew total year sales to the highest level in nine years, sustained profitability, generated operating cash flow and repaid nearly all of the SWE acquisition-related debt,” added Popielec. “While the outlook for demand in our end markets is less visible than we would like, we will remain focused on what we can control: organic growth initiatives, including completing transformational new product development projects and investments in strategic capital expenditure, and synergistic acquisitions.”

Fourth Quarter 2020 Financial Results

Revenue was $29.0 million, a decrease of $2.0 million or 6.6%, compared to $31.0 million for the fourth quarter of 2019, as a 25.7% increase in core battery sales across diversified end markets was offset by lower oil & gas market and Communications Systems sales.   Battery & Energy Products revenues increased 0.7% to $25.3 million, compared to $25.1 million last year, as a 94.3% increase in medical battery sales, especially those used in ventilators, respirators and infusion pumps, and an 18.8% increase in government/defense sales, were offset by a 67.4% decline in oil & gas market sales. Communications Systems sales decreased 37.6% to $3.7 million compared to $5.9 million for the same period last year, primarily reflecting 2019 shipments of vehicle amplifier-adaptor systems to support the U.S. Army’s Network Modernization initiatives under the delivery orders announced in October 2018. These orders were completed in the second quarter of 2020. The net adverse impact of COVID-19 on revenues for the 2020 fourth quarter was approximately $2.6 million as a substantial increase in demand for medical batteries was more than offset primarily by weakened demand in the oil & gas and international industrial markets.      Gross profit was $7.4 million, or 25.4% of revenue, compared to $9.4 million, or 30.2% of revenue, for the same quarter a year ago.   Battery & Energy Products’ gross margin was 25.2%, compared to 26.4% last year, primarily reflecting lower volume for oil & gas market batteries. Communications Systems gross margin was 26.3% compared to 46.1% last year, due to sales mix and lower volume in 2020.      

Operating expenses were $6.1 million compared to $6.9 million last year, a reduction of 10.9%.    Operating expenses were 21.2% of revenue compared to 22.2% for the year-earlier period.

Operating income was $1.2 million compared to $2.5 million last year, and operating margin was 4.2% compared to 8.0% last year.   The net adverse impact of COVID-19 on operating income for the 2020 fourth quarter was approximately $1.2 million.

Other income of $1.6 million compared to other expense of $0.3 million last year, primarily reflecting a $1.6 million gain realized during the fourth quarter upon favorable resolution of Ultralife’s claim in a class action lawsuit.

Net income was $2.1 million or $0.13 per diluted share on a GAAP basis using the U.S. statutory tax rate, compared to net income of $1.6 million, or $0.10 per diluted share for the fourth quarter of 2019. Adjusted EPS was $0.17 on a diluted basis for the fourth quarter of 2020, compared to $0.13 for the 2019 period. Adjusted EPS excludes the provision for deferred taxes of $0.6 million which primarily represents non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future. The net adverse impact of COVID-19 on Adjusted EPS for the 2020 fourth quarter was approximately $0.07.  

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense and excluding the $1.6 million gain on the class action settlement, for the fourth quarter was $2.2 million or 7.6% of sales and for the 2020 trailing twelve-month period was $9.7 million or 9.0% of sales.

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of Adjusted EPS to EPS and Adjusted EBITDA to Net Income Attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

Conference Call Information

Ultralife will hold its fourth quarter earnings conference call today at 8:30 AM ET. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include the impact of COVID-19, potential reductions in revenues from key customers, acceptance of our new products on a global basis and uncertain global economic conditions. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS(Dollars in Thousands)
(Unaudited)
    
ASSETS
     
 December 31, 2020 December 31,2019 
Current Assets:    
Cash$10,653  $7,405  
Trade Accounts Receivable, Net 21,054   30,106  
Inventories, Net 28,193   29,759  
Prepaid Expenses and Other Current Assets 4,596   3,103  
Total Current Assets 64,496   70,373  
     
Property, Equipment and Improvements, Net 22,850   22,525  
Goodwill 27,018   26,753  
Other Intangible Assets, Net 9,209   9,721  
Deferred Income Taxes, Net 11,836   13,222  
Other Non-Current Assets 2,292   1,963  
Total Assets$137,701  $144,557  
             
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:     
Accounts Payable$10,839  $9,388  
Current Portion of Long-Term Debt, Net 1,361   1,372  
Accrued Compensation and Related Benefits 1,748   1,655  
Accrued Expenses and Other Current Liabilities 4,758   4,775  
Total Current Liabilities 18,706   17,190  
Long-Term Debt -   15,780  
Deferred Income Taxes 515   559  
Other Non-Current Liabilities 1,557   1,278  
Total Liabilities 20,778   34,807  
     
Shareholders' Equity:    
Common Stock 2,037   2,026  
Capital in Excess of Par Value 185,464   184,292  
Accumulated Deficit (47,598)  (52,830) 
Accumulated Other Comprehensive Loss (1,782)  (2,531) 
Treasury Stock (21,321)  (21,231) 
Total Ultralife Equity 116,800   109,726  
Non-Controlling Interest 123   24  
Total Shareholders’ Equity 116,923   109,750  
     
Total Liabilities and Shareholders' Equity$137,701  $144,557  

ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In Thousands Except Per Share Amounts)
(Unaudited)
        
 Three-Month Period Ended Year Ended
 December 31, December 31, December 31, December 31,
  2020   2019  2020   2019
Revenues:       
Battery & Energy Products$25,291  $25,120 $91,907  $83,996
Communications Systems 3,685   5,903  15,805   22,799
Total Revenues 28,976   31,023  107,712   106,795
        
Cost of Products Sold:       
Battery & Energy Products 18,910   18,489  68,507   61,183
Communications Systems 2,715   3,179  10,046   14,447
Total Cost of Products Sold 21,625   21,668  78,553   75,630
        
Gross Profit 7,351   9,355  29,159   31,165
        
Operating Expenses:       
Research and Development 1,518   2,153  5,947   6,805
Selling, General and Administrative 4,618   4,730  17,511   16,992
Total Operating Expenses 6,136   6,883  23,458   23,797
        
Operating Income  1,215   2,472  5,701   7,368
        
Other (Income) Expense:       
Gain on Litigation Settlement (1,593)  -  (1,593)  -
Other Expense, Net 9   296  271   597
Total Other (Income) Expense (1,584)  296  (1,322)  597
        
Income Before Income Taxes 2,799   2,176  7,023   6,771
Income Tax Provision 682   515  1,692   1,457
        
Net Income  2,117   1,661  5,331   5,314
        
Net Income Attributable to Non-Controlling Interest 9   35  99   109
        
Net Income Attributable to Ultralife Corporation$2,108  $1,626 $5,232  $5,205
        
        
Net Income Per Share Attributable to Ultralife Common Shareholders – Basic$.13  $.10 $.33  $.33
        
Net Income Per Share Attributable to Ultralife Common Shareholders – Diluted$.13  $.10 $.33  $.32
        
Weighted Average Shares Outstanding – Basic 15,940   15,861  15,902   15,783
        
Weighted Average Shares Outstanding – Diluted 16,122   16,205  16,096   16,179

Non-GAAP Financial Measures:

Adjusted Earnings Per Share

In evaluating our business, we consider and use Adjusted EPS, a non-GAAP financial measure, as a supplemental measure of our business performance in addition to GAAP financial measures. We define Adjusted EPS as net income attributable to Ultralife Corporation excluding the provision for deferred taxes divided by our weighted average shares outstanding on both a basic and diluted basis. We believe that this information is useful in providing period-to-period comparisons of our results by reflecting the portion of our tax provision that we expect will be offset by our U.S. net operating loss carryforwards and other tax credits for the foreseeable future. We reconcile Adjusted EPS to EPS, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on Adjusted EPS as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of Adjusted EPS to EPS and net income attributable to Ultralife Corporation.

ULTRALIFE CORPORATION AND SUBSIDIARIES
CALCULATION OF ADJUSTED EPS
(In Thousands Except Per Share Amounts)
(Unaudited)

 Three-Month Period Ended
 December 31, 2020 December 31, 2019
 Amount Per Basic Share Per Diluted Share Amount Per Basic Share Per Diluted Share
Net Income Attributable to Ultralife Corporation$2,108 $.13 $.13 $1,626 $.10 $.10
Deferred Tax Provision 565 .04 .04  410 .03 .03
Adjusted Net Income$2,673 $.17 $.17 $2,036 $.13 $.13
            
Weighted Average Shares Outstanding  15,940 16,122   15,861 16,205
            

 Year Ended
 December 31, 2020 December 31, 2019
 Amount Per Basic Share Per Diluted Share Amount Per Basic Share Per Diluted Share
Net Income Attributable to Ultralife Corporation$5,232 $.33 $.33 $5,205 $.33 $.32
Deferred Tax Provision 1,386 .09 .08  1,211 .08 .08
Adjusted Net Income$6,618 $.42 $.41 $6,416 $.41 $.40
            
Weighted Average Shares Outstanding  15,902 16,096   15,783 16,179
            
            

Adjusted EBITDA

In evaluating our business, we consider and use Adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define Adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile Adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on Adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of Adjusted EBITDA to net income attributable to Ultralife Corporation.

ULTRALIFE CORPORATION AND SUBSIDIARIES
CALCULATION OF ADJUSTED EBITDA
(Dollars in Thousands)
(Unaudited)

 Three-Month Period Ended Year Ended
 December 31, 2020 December 31, 2019 December 31, 2020 December 31, 2019
        
Net Income Attributable to Ultralife Corporation$2,108  $1,626 $5,232  $5,205
Adjustments:       
Interest and Financing Expense, Net 64   200  436   539
Income Tax Provision 682   515  1,692   1,457
Depreciation Expense 597   672  2,340   2,220
Amortization of Intangible Assets and Financing Fees 166   165  646   569
Stock-Based Compensation Expense 187   235  943   753
Gain on Litigation Settlement (1,593)  -  (1,593)  -
Non-Cash Purchase Accounting Adjustments -   -  -   264
Adjusted EBITDA$2,211  $3,413 $9,696  $11,007

Company Contact: Investor Relations Contact:
Ultralife Corporation LHA 
Philip A. Fain  Jody Burfening
(315) 210-6110 (212) 838-3777
pfain@ulbi.com jburfening@lhai.com

 

Primary Logo

Source: Ultralife Corporation


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Globe Newswire, Press Releases

Related Entities

Earnings, Definitive Agreement